Financial Data and Key Metrics Changes - For the full year 2025, the company reported net product revenue of $155.4 million, representing a 172% increase year-over-year, with double-digit sequential quarterly growth throughout the year [5][34] - In Q4 2025, net product revenue reached $52.8 million, reflecting a 37% sequential growth over Q3 [20][34] - The company ended 2025 with approximately $441 million in cash and no debt, providing a strong financial foundation for future growth [9][38] Business Line Data and Key Metrics Changes - OJEMDA remains the primary revenue driver, with over 4,600 total prescriptions for the year, marking an increase of over 180% compared to 2024 [5][21] - The company achieved a median duration of therapy trending towards 19 months for commercial PLGG patients, indicating strong persistency [47] Market Data and Key Metrics Changes - The company anticipates global expansion for OJEMDA, with regulatory approvals being prepared for markets outside the U.S., including Europe [8] - Coverage rates for PLGG remain above 95%, with over 90% of patients approved on the first request, facilitating quick therapy initiation [23] Company Strategy and Development Direction - The company aims to solidify OJEMDA as the second-line standard of care in pediatric low-grade glioma (PLGG) and is focused on driving new patient starts and optimizing treatment persistence [22][24] - The acquisition of Mersana Therapeutics is seen as a strategic move to enhance the pipeline, particularly with the Emi-Le program targeting adenoid cystic carcinoma [39] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory for 2026, reiterating guidance for OJEMDA net product revenue of $225 million to $250 million [5][38] - The company is optimistic about the potential of OJEMDA to become the standard of care in the second-line setting, supported by positive clinical data and physician confidence [22][24] Other Important Information - The company is advancing multiple pipeline programs, including DAY301 and Emi-Le, which target significant unmet medical needs in oncology [27][30] - The three-year follow-up data from the FIREFLY-1 trial demonstrated a 53% objective response rate for OJEMDA, reinforcing its clinical efficacy [12][18] Q&A Session Summary Question: How does the company maintain and improve persistency for OJEMDA? - Management highlighted that current persistency is strong, with median therapy duration trending towards 19 months, and identified opportunities to enhance persistency through targeted patient support programs and physician education [47][48] Question: What are the expectations for the upcoming Emi-Le data? - Management indicated that they expect to present substantial data supporting the move into registrational trials, focusing on the antitumor activity and safety profile of Emi-Le [52][54] Question: What early trends are observed in Q1 2026? - Management noted that demand remains strong in Q1, with confidence in achieving the reiterated revenue guidance for the year [62][63] Question: Can the company provide insights on the time to next treatment analysis? - Management explained that the analysis shows that many patients continue therapy despite radiographic progression, emphasizing the importance of clinical signs over imaging results in treatment decisions [66][68] Question: What is the expected response rate for Emi-Le in ACC? - Management stated that they aim for a robust data package that clearly delineates the performance of Emi-Le compared to existing therapies, which have poor response rates [85][86]

FEBRUARY 2026 Fourth Quarter & Full-Year 2025 Financial Results & Corporate Progress In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this presentation, and although we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted ...

Financial Performance - The company has incurred significant net losses since its inception, reporting net losses of $107.3 million, $95.5 million, and $188.9 million for the years ended December 31, 2025, 2024, and 2023, respectively, with an accumulated deficit of $661.4 million as of December 31, 2025[246]. - The company expects to incur increasing levels of operating losses for the foreseeable future, particularly as it advances tovorafenib, Emi-Le, and DAY301 through clinical development[246]. - The company’s financial condition and operating results are expected to fluctuate significantly from quarter to quarter and year to year due to various factors beyond its control[249]. - As of December 31, 2025, the company had $441.1 million in cash, cash equivalents, and short-term investments, which is estimated to be sufficient for at least twelve months to meet capital requirements[261]. - The company anticipates needing additional capital to complete clinical development programs for current product candidates and to obtain marketing authorization[262]. - The company may face challenges in raising additional funds due to potential worsening global economic conditions and disruptions in financial markets[264]. - The company has incurred and will continue to incur costs associated with operating as a public company, including hiring experienced personnel and developing IT systems[261]. - The company may incur substantial costs to ensure compliance with evolving healthcare laws and regulations, impacting financial performance[389]. Revenue Generation and Commercialization - The company generated approximately $212.6 million in revenue from product sales of OJEMDA as of December 31, 2025, with future revenues highly dependent on the successful commercialization of OJEMDA, which received FDA approval in April 2024[246][250]. - The company expects to incur significant expenses related to the commercialization of OJEMDA and the development of product candidates Emi-Le and DAY301, including manufacturing, marketing, and distribution costs[261]. - Successful commercialization of OJEMDA will depend on negotiations with third-party payors, which cannot be predicted[324]. - The availability of coverage and adequate reimbursement by third-party payors is essential for patients to afford treatments, impacting sales revenue[326]. - Coverage determination processes for pediatric products are often time-consuming and costly, with no assurance of consistent reimbursement[327]. - The potential commercial opportunity for OJEMDA may be limited if competitors develop safer or more effective products[308]. - OJEMDA and product candidates Emi-Le and DAY301 may not achieve adequate market acceptance necessary for commercial success globally[323]. Clinical Development and Regulatory Challenges - The company is focusing on the pivotal Phase 3 FIREFLY-2 trial of tovorafenib as a potential front-line therapy in pLGG, with no assurance of success in ongoing clinical trials or obtaining marketing authorization for its product candidates[253]. - Clinical trials for product candidates are expensive and time-consuming, with uncertain outcomes that may affect the timeline for marketing authorization[266]. - The outcome of clinical trials is uncertain, with significant risks of failure, which could negatively impact commercial prospects and revenue generation[282][283]. - The company may experience delays or failures in clinical trials that could prevent or delay marketing authorization for its product candidates[275]. - The company must comply with ongoing regulatory requirements for any product with marketing authorization, including OJEMDA, which could involve substantial resources[381]. - The FDA approval process for product candidates is expensive and uncertain, with a small percentage of drugs successfully completing the process[339]. - The company may need to conduct additional preclinical studies if formulation or manufacturing changes are made to product candidates, which could delay trials[277]. - The company faces additional hurdles in clinical trials for pediatric populations, including potential refusals from regulatory agencies and challenges in demonstrating optimized dosing[280]. Competition and Market Landscape - The company may face competition from existing therapies and new products in development, particularly in the oncology sector, which could affect market access[295][297]. - Five MEK inhibitors have been approved by the FDA, with some targeting pediatric patients, indicating a competitive landscape for the company's product candidates[299]. - The BRAF V600E subset represents approximately 10%-20% of BRAF-altered pediatric low-grade glioma (pLGG), with recent approvals for competing therapies impacting patient enrollment[298]. - The company faces significant competition from larger pharmaceutical and biotechnology firms with greater resources and established market presence[305]. Supply Chain and Manufacturing Risks - The company relies on third-party manufacturers in China for the production of OJEMDA, DAY301, and Emi-Le, which increases the risk of supply chain disruptions and delays in clinical trials or commercialization[427]. - The company faces risks related to a limited number of suppliers for raw materials, which could lead to delays in clinical trials and adversely affect business operations[439]. - Increased U.S. tariffs and trade restrictions could compress margins by raising costs on imported raw materials and product intermediates, particularly for OJEMDA[440]. - The company has sufficient API inventory for commercial and clinical use but anticipates that tariffs on imports from China may increase future costs, negatively impacting financial results[428]. Regulatory Designations and Approvals - The company has been granted breakthrough therapy designation for tovorafenib in patients with advanced pLGG, which may facilitate a more efficient clinical development path[346]. - The FDA granted rare pediatric disease designation for OJEMDA in May 2021, with marketing authorization approved on April 23, 2024, for patients aged 6 months and older with specific genetic alterations[367]. - The company may apply for orphan drug designation for additional product candidates in the future, which could provide further market exclusivity and financial incentives[361]. - The FDA may grant Fast Track designation for drugs intended to treat serious conditions, but this designation does not guarantee expedited approval[345]. Compliance and Legal Risks - The company faces significant penalties, including criminal and civil penalties, if found in violation of healthcare laws and regulations[387]. - The Affordable Care Act (ACA) imposes annual fees and taxes on manufacturers of certain branded prescription drugs, affecting profitability[391]. - The Inflation Reduction Act (IRA) allows the U.S. Department of Health and Human Services to negotiate prices for certain drugs, impacting revenue potential[394]. - Legislative changes may lead to increased scrutiny over drug pricing and reimbursement methodologies, affecting market access[394]. Operational Challenges - The company has limited experience in commercializing products, which may hinder the success of its first product, OJEMDA[416]. - Establishing sales, marketing, and distribution capabilities involves significant expenses and risks, which could negatively affect commercialization efforts[417]. - The company relies on third parties for clinical trials and research, and any failure by these parties could delay development programs and increase costs[420]. - Compliance with Good Clinical Practice (GCP) requirements is essential, and failure to do so may result in unreliable data and additional trials being required[422].

Financial Performance - As of December 31, 2025, the company reported cash, cash equivalents, and short-term investments of $441.1 million[5]. - OJEMDA net revenue for Q3 2025 was $38.5 million, up from $20.1 million in Q3 2024, representing a 91.5% increase[42]. - Total revenue for the nine months ended September 30, 2025, was $104.5 million, compared to $102.0 million for the same period in 2024, showing a 2.5% increase[42]. - The company reported a net loss of $19.7 million for Q3 2025, compared to a net income of $37.0 million in Q3 2024[42]. - Research and Development expenses for the nine months ended September 30, 2025, were $107.2 million, down from $165.9 million in 2024, a decrease of 35.4%[42]. - Selling, General and Administrative expenses for the nine months ended September 30, 2025, were $86.4 million, slightly up from $85.7 million in 2024[42]. Product Development and Approval - OJEMDA received FDA approval in April 2024 for pediatric patients aged 6 months and older with specific BRAF alterations[4]. - The company plans to advance the Emi-Le program with a path toward registration and has acquired Mersana Therapeutics[5]. - The pivotal Phase 3 trial of tovorafenib in front-line pediatric low-grade glioma (pLGG) is expected to complete enrollment in 1H 2026, with topline data expected mid-2027[31]. - The company plans to complete FIREFLY-2 trial enrollment in the first half of 2026, enabling mid-2027 data readout and potential approval in 2028[43]. - The company anticipates delivering Phase 1 clinical data for Emi-Le by mid-2026 and progressing to later-stage development[43]. - DAY301 is a next-generation antibody-drug conjugate (ADC) targeting PTK7, with Phase 1a data expected in 2H 2026[37]. Market Opportunity and Growth - The company aims to solidify OJEMDA as the second-line standard of care (SOC) in relapsed or refractory pediatric low-grade glioma (pLGG) and expand its market opportunity[5]. - The company anticipates a revenue opportunity exceeding $1 billion across three high unmet need indications[7]. - The number of treatment decisions for relapsed or refractory pediatric low-grade glioma (pLGG) is approximately 1,100 annually, with significant room for market share growth for OJEMDA[14]. - OJEMDA's estimated net product revenues for Q4 2025 are projected to be $52.8 million, reflecting a 37% growth compared to Q3 2025 and a 172% increase from 2024[15]. - The expected net product revenue for OJEMDA in 2026 is estimated to be between $225 million and $250 million, indicating over 50% growth compared to 2025[16]. - OJEMDA has achieved a 60% increase in 2L adoption over the past 12 months, with a growing number of healthcare providers selecting it as their treatment of choice[17]. - The company anticipates a significant increase in prescribing accounts, with 28% sequential growth in accounts treating four or more patients[18]. - OJEMDA's commercial execution is expected to drive strong growth in 2026, supported by favorable payer dynamics and a solidified position as the second-line standard of care[16]. Clinical Data and Efficacy - OJEMDA's median duration of response is reported at 19.4 months, with 77% of patients treatment-free for at least 12 months following 24 months of therapy[12]. - 75% of patients in the Expanded Access Program (EAP) who reached 24 months on OJEMDA continued treatment, demonstrating strong persistency[17]. - The Phase 2 FIREFLY-1 trial reported a 53% overall response rate (ORR) among patients, with 58% completing 26 or more treatment cycles[23]. - Median tumor size change from baseline after the last dose was -51% at 3 months and -55% at 6 months post-treatment[26]. - All 8 patients receiving OJEMDA retreatment were still on therapy at the time of data cutoff, with a median change in tumor size of -38.3%[27]. - In the updated 3-year analysis, 38 patients had RAPNO-defined progressive disease (PD) while on OJEMDA[26]. - No new safety signals were observed in the 3-year update, with 66% of treatment-related adverse events (TRAEs) being grade ≥3[29]. - 77% of 39 patients were treatment-free for at least 12 months, with the median treatment-free interval not yet reached[28]. Intellectual Property - The patent portfolio for OJEMDA includes a composition of matter patent extending to mid-2036, with additional protections potentially extending into the 2040s[20]. Strategic Partnerships - The company is focused on global commercial expansion through partnerships, including a license agreement with Ipsen for OJEMDA outside the U.S.[6]. - The company aims to expand OJEMDA globally, extending its commercial opportunity through collaboration with Ipsen[43].

OJEMDA™ 2025 momentum reflected by Q4 and full year net product revenues of $52.8 million and $155.4 million, respectively 2026 U.S. net product revenue projected at $225 - $250 million Expanded pipeline with January 2026 acquisition of Mersana Therapeutics; Emi-Le in Phase 1 trial for adenoid cystic carcinoma (ACC) Day One to host conference call and webcast today, February 24, 4:30 p.m. ET BRISBANE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or th ...

Core Viewpoint - Day One Biopharmaceuticals is set to report its financial results and corporate progress for Q4 and full-year 2025 on February 24, 2026, highlighting its commitment to developing targeted therapies for life-threatening diseases, particularly in pediatric cancer [1]. Group 1: Company Overview - Day One Biopharmaceuticals is a commercial-stage biopharmaceutical company focused on addressing the unmet needs in pediatric cancer treatment [3]. - The company aims to redefine cancer drug development and improve outcomes for patients of all ages from the moment of diagnosis [3]. Group 2: Pipeline and Development - Day One's pipeline includes tovorafenib (OJEMDA™), DAY301, and Emi-Le (emiltatug ledadotin), a novel antibody drug conjugate targeting the B7-H4 protein, currently in clinical development for adenoid cystic carcinoma (ACC) [4]. - The recent acquisition of Mersana Therapeutics enhances Day One's capabilities in developing targeted cancer treatments [4]. Group 3: Communication and Accessibility - A live conference call and webcast will be available for stakeholders to access financial results and corporate updates [2]. - An archived version of the webcast will be accessible for 30 days post-event, ensuring continued engagement with investors and the public [2].

Group 1 - Day One Biopharmaceuticals, Inc. (DAWN) closed at $11.16, reflecting a 26.1% gain over the past four weeks, with a mean price target of $22.44 indicating a potential upside of 101.1% [1] - The average price target ranges from a low of $16.00 to a high of $29.00, with a standard deviation of $4.59, suggesting a variability in analyst estimates [2] - Analysts have shown increasing optimism regarding DAWN's earnings prospects, as indicated by a positive trend in earnings estimate revisions, with a 20.6% increase in the Zacks Consensus Estimate for the current year [11][12] Group 2 - DAWN currently holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - The clustering of price targets with a low standard deviation indicates a high degree of agreement among analysts about the stock's price movement direction [9] - While price targets should not be the sole basis for investment decisions, they can provide a useful guide for potential price movement [14]

Core Insights - The recent tariff noise is impacting the market, and investors are advised to focus on long-term investment themes rather than reacting to headlines [1][7] Market Performance - In 2025, markets initially fell nearly 15% by April due to tariff fears, but those who remained invested saw a 39% rebound by year-end, highlighting the importance of long-term trends [2] Investment Opportunities - Investors should prioritize long-term growth opportunities, particularly in the AI sector, with trillions expected in infrastructure investments by 2030 [3] - Comfort Systems USA Inc. (NYSE:FIX) and Duke Energy Corp. (NYSE:DUK) are highlighted as stable investment options, with Duke trading at 17X forward earnings and offering a 3.7% dividend yield [4] Promising Sectors - Aerospace and defense sectors are expected to benefit from rising global military budgets, while small-cap biotech is positioned to gain from patent cliffs and M&A activity [5] - Notable companies in these sectors include L3 Harris Technology Inc. (NYSE:LHX) in defense and Indivior PLC (NASDAQ:INDV) and Day One Biopharmaceuticals Inc. (NASDAQ:DAWN) in biotech [5] Future Market Outlook - In 2026, investors who align with their risk tolerance and "follow the money" may find attractive entry points despite ongoing market volatility [6] - Current market conditions are turbulent due to renewed tariff threats, with the S&P 500 and Nasdaq 100 both sliding around 2%, marking their worst sessions in over three months [7][8]

Core Viewpoint - Day One Biopharmaceuticals, Inc. (DAWN) has seen a 22.5% increase in share price over the past four weeks, closing at $10.73, with a mean price target of $22.25 indicating a potential upside of 107.4% according to Wall Street analysts [1]. Price Targets and Analyst Estimates - The mean estimate consists of eight short-term price targets with a standard deviation of $4.86, where the lowest estimate of $16.00 suggests a 49.1% increase, and the highest estimate of $29.00 indicates a potential surge of 170.3% [2]. - A low standard deviation signifies a high degree of agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9]. Earnings Estimates and Analyst Optimism - Analysts are optimistic about DAWN's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which has shown a strong correlation with near-term stock price movements [11]. - The Zacks Consensus Estimate for the current year has increased by 20.6% over the past month, with one estimate rising and no negative revisions [12]. - DAWN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential upside [13]. Caution on Price Targets - While price targets are often sought after by investors, they can mislead and should not be the sole basis for investment decisions, as empirical research indicates that they rarely predict actual stock price movements [7][10].

Core Viewpoint - Day One Biopharmaceuticals, Inc. (DAWN) experienced a significant stock rally of 26.7% due to strong preliminary sales figures for its drug Ojemda, which is aimed at treating pediatric low-grade glioma [1][2]. Financial Performance - Preliminary net product revenues for Ojemda were approximately $52.8 million for Q4 2025 and $155.4 million for the full year 2025, marking a 172% year-over-year increase [3]. - For full-year 2026, the company anticipates Ojemda net product revenue to be between $225 million and $250 million, indicating a projected 53% year-over-year growth at the midpoint [3]. Earnings Expectations - The company is expected to report a quarterly loss of $0.18 per share, reflecting a year-over-year change of +73.9%, with revenues projected at $43.25 million, up 48.1% from the previous year [4]. - The consensus EPS estimate for the upcoming quarter has remained unchanged over the last 30 days, suggesting that stock price movements may be influenced by trends in earnings estimate revisions [5]. Industry Context - Day One Biopharmaceuticals is part of the Zacks Medical - Biomedical and Genetics industry, where IDEAYA Biosciences, Inc. (IDYA) also operates, having experienced a 1.4% decline in the last trading session [6]. - IDEAYA's consensus EPS estimate for its upcoming report has remained unchanged at -$1.03, representing a +30.9% change from the previous year [7].